A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo

Clinical Cancer Research

Volumn 12, Issue 8, 2006, Pages 2583-2590

  Cooper, Andrew C ^a   Karp, Russell M ^b   Clark, Edward J ^b   Taghizadeh, Nazbeh R ^b   Hoyt, Jennifer G ^b   Labenski, Matthew T ^b   Murray, Michael J ^c   Hannig, Gerhard ^b   Westlin, William F ^b   Thompson, Charles D ^d  

^a Department of Cell Biology ^*

^b Praecis Pharmaceuticals Incorporated   (United States)

^c Memory Pharmaceuticals Corporation   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CARBAMOYL 2 METHYLPROPYLCARBAMIC ACID 5 METHOXY 4 [2 METHYL 3 (3 METHYL BUT 2 ENYL)OXIRANYL] 1 OXA SPIROL [2.5]OCT 6 YL ESTER; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; METHIONYL AMINOPEPTIDASE; METHIONYL AMINOPEPTIDASE 2; METHIONYL AMINOPEPTIDASE 2 INHIBITOR; PPI 2458; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; FEMALE; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOMA CELL LINE; MALE; MONKEY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

AMINOPEPTIDASES; ANIMALS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXY COMPOUNDS; FEMALE; GERMINAL CENTER; HUMANS; LYMPHOCYTE COUNT; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MACACA FASCICULARIS; METALLOENDOPEPTIDASES; MICE; MICE, SCID; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; VALINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33646391501     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0871     Document Type: Article

References (38)

1. Fisher RI. Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. Semin Oncol 2003;30:3-9.
2. Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology (Am Soc Hematol Educ Program) 2002;1:241-62.
3. Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002;99:282-9.
4. Winter JN, Andersen J, Reed JC, et al. BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood 1998;91:1391-8.
5. Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A 2003;100:7259-64.
6. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 2001;13:325-34.
7. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
8. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
9. Babior BM, Stossel TP. Hematology: a pathophysiological approach. 3rd ed. New York: Churchill Livingstone; 1994. p. 413-23.
10. Horning SJ. Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol 2003;30:29-34.
11. Forero A, Lobuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol 2003;30:1-5.
12. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-35.
13. Li X, Chang YH. Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Proc Natl Acad Sci U S A 1995;92:12357-61.
14. Li X, Chang YH. Evidence that the human homologue of a rat initiation factor-2 associated protein (p67) is a methionine aminopeptidase. Biochem Biophys Res Commun 1996;227:152-9.
15. Chang YH, Teichert U, Smith JA. Molecular cloning, sequencing, deletion, and overexpression of a methionine aminopeptidase gene from Saccharomyces cerevisiae. J Biol Chem 1992;267:8007-11.
16. Sin N, Meng L, Wang MQ, et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A 1997;94:6099-103.
17. Griffith EC, Su Z, Turk BE, et al. Methionine amino-peptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 1997;4:461-71.
18. Griffith EC, Su Z, Niwayama S, et al. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci U S A 1998;95:15183-8.
19. Turk BE, Griffith EC, Wolf S, et al. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 1999;6:823-33.
20. Abe J, Zhou W, Takuwa N, et al. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994;54:3407-12.
21. Kusaka M, Sudo K, Matsutani E, et al. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994;69:212-6.
22. Milkowski DM, Weiss RA. TNP-470. In: Teicher BA, editor. Antiangiogenic agents in cancer therapy. Totowa (New Jersey): Humana Press; 1999. p. 385-98.
23. Kanno T Endo H, Takeuchi K, et al. High expression of methionine aminopeptidase type 2 in germinal center B cells and their neoplastic counterparts. Lab Invest 2002;82:893-901.
24. Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity. Am J Pathol 2001;159:721-31.
25. Selvakumar P, Lakshmikuttyamma A, Kanthan R, et al. High expression of methionine aminopeptidase 2 in human colorectal adenocarcinomas. Clin Cancer Res 2004;10:2771-5.
26. Bernier SG, Lazarus DD, Clark E, et al. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci U S A 2004;101:10768-73.
27. Bernier SG, Taghizadeh N, Thompson CD, Westlin WF, Hannig, G. Methionine aminopeptidases type I and type II are essential to control cell proliferation. J Cell Biochem 2005;95:1191-203.
28. Antoine N, Bours V, Heinen E, Simar LJ, Castronovo V. Simulation of human B-lymphocyte proliferation by AGM-1470, a potent inhibitor of angiogenesis. J Natl Cancer Inst 1995;87:136-9.
29. Antoine N, Daukandt M, Locigno R, et al. The potent angioinhibin AGM-1470 stimulates normal but not human tumoral lymphocytes. Tumori 1996;82:27-30.
30. Turk BE, Su Z, Liu JO. Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Bioorg Med Chem 1998;6:1163-9.
31. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997;276:589-92.
32. Fukuda T, Yoshida T, Okada S, et al. Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med 1997;186:439-48.
33. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 1997;16:161-70.
34. Vasanwala FH, Kusam S, Toney LM, Dent AL. Repression of AP-1 function : a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol 2002;169:1922-9.
35. Wang J, Lou P, Henkin J. Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 2000;77:465-73.
36. Park E, Kalunta CI, Nguyen TT, et al. TNF-α inhibits anti-IgM-mediated apoptosis in Ramos cells. Exp Cell Res 1996;226:1-10.
37. Lazarus DD, Bernier SG, Labenski MT, et al. Inhibition of primary tumor growth by PPI-2458, a methionine aminopeptidase-2 inhibitor: dose and schedule responses. Proceedings of the 2003 AACR-NIH-EORTC International Conference. Clin Cancer Res 2003;9:6112S.
38. Hollingshead MG, Kaur G, Borgel SD, et al. In vivo efficacy of PPI-2458 (NSC 720735), a novel fumagillin analogue with oral bioavailability. Proceedings of the 2003 AACR-NIH-EORTC International Conference. Clin Cancer Res 2003;9:6213S.